[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-363817-105":59,"doc-detail-363817-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","aptamer-based-inhibition-of-mnk1-reduces-pancreatic-ductal-adenocarcinoma-growth-by-targeting-cancer-stem-cells","Aptamer-based inhibition of MNK1 reduces pancreatic ductal adenocarcinoma growth by targeting cancer stem cells","","Pancreatic ductal adenocarcinoma remains highly lethal due to late detection, early metastasis, and therapy resistance. Cancer stem cells contribute to PDAC aggressiveness and treatment failure, and MNK1 is overexpressed and supports tumor progression and CSC maintenance. This study evaluates apMNKQ2, a DNA aptamer targeting MNK1, to therapeutically impair CSCs and reduce PDAC tumor burden in patient-derived xenografts.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/aptamer-based-inhibition-of-mnk1-reduces-pancreatic-ductal-adenocarcinoma-growth-by-targeting-cancer-stem-cells/363817/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/aptamer-based-inhibition-of-mnk1-reduces-pancreatic-ductal-adenocarcinoma-growth-by-targeting-cancer-stem-cells/363817.png","ImageObject",300,407,{"name":92,"@type":93},"Anna Hans","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-01","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":34},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What disease and biological target does the study focus on?","Question",{"text":112,"@type":113},"The study focuses on pancreatic ductal adenocarcinoma (PDAC) and targets MAP kinase-interacting kinase 1 (MNK1), which is implicated in tumor progression and cancer stem cell maintenance.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How was apMNKQ2 evaluated in the experiments?",{"text":117,"@type":113},"apMNKQ2 effects were assessed using PDAC patient-derived xenograft (PDX) cell lines and in vivo mouse models, including assays for viability, apoptosis, cell cycle, migration, EMT, and CSC properties, plus biodistribution and pharmacokinetics.",{"name":119,"@type":110,"acceptedAnswer":120},"What key anti-tumor and anti-CSC outcomes were reported?",{"text":121,"@type":113},"apMNKQ2 downregulated MNK1 and anti-apoptotic proteins, disrupted proliferation and cell cycle progression, inhibited migration/angiogenesis and lung colonization, and strongly targeted PDAC CSCs—reducing CSC markers, clonogenicity, and in vivo tumor initiation over 600-fold.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},363817,1790695439,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":34,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},5909892332657,"https://ap-avatar.wpscdn.com/davatar_994ba38a5ba835b3df7d355c54d3ed8d","Pérez‑Ruiz et al.  \nJournal of Biomedical Science (2026) 33:72 [https://doi.org/10.1](https://doi.org/10.1) 186/s12929‑026‑01275‑6  \nRESEARCH Open Access  \nAptamer‑based inhibition of MNK1 reduces   pancreatic ductal adenocarcinoma growth by targeting cancer stem cells  \nAlberto Pérez‑Ruiz 1†, Laura Ruiz‑Cañas2,3,4†, Sandra Batres2,3†, Raquel Ferreras‑Martín 1, Celia Pinto‑Díez 1,5, Balbino Yagüe2,3, Maria Isabel Pérez‑Morgado 1, Silvia Sacristán1, Ignacio Ruz‑Caracuel6,8,9, Sonia Camaño Páez4, Isabel Sanchez‑Perez2,3,7,10, Víctor M. González 1, Sonia Alcalá1,2,3*, María Elena Martín 1* and Bruno Sainz Jr.2,3*  \nAbstract  \nBackground Pancreatic ductal adenocarcinoma (PDAC) remains one of the deadliest cancers due to late diagnosis, early metastasis and resistance to therapy. Cancer stem cells (CSCs) have been implicated in PDAC aggressiveness and treatment failure. MAP kinase‑interacting kinase 1 (MNK1) is overexpressed in PDAC and plays a critical role in tumor progression and CSC maintenance. Here, we show the potential of apMNKQ2, a DNA aptamer targeting MNK1, to therapeutically target CSCs and reduce PDAC tumor burden in patient‑derived xenografts (PDXs) .  \nMethods PDX cell lines and in vivo mouse models were used to assess the effects of apMNKQ2 on cell viability, apoptosis, cell cycle progression, migration, epithelial‑to‑mesenchymal transition (EMT) and CSC properties. Func‑ tional CSC targeting was validated through clonogenic and self‑renewal assays as well as extreme limiting dilution analysis. Systemic administration of free apMNKQ2 was tested for biodistribution, pharmacokinetics, toxicity, and anti‑ tumor efficacy at escalating doses.  \nResults apMNKQ2 downregulated MNK1 and anti‑apoptotic proteins (MCL1, XIAP), impaired cell proliferation, induced apoptosis, and disrupted cell cycle progression in PDX PDAC cells. Importantly, apMNKQ2 also inhibited migration, mesenchymal properties and angiogenesis in vitro, and lung colonization in vivo. Notably, apMNKQ2 strongly targeted PDAC CSCs, reducing CD24, CD133, CXCR4 and ALDH expression, clonogenicity and in vivo tumor initiation over 600‑fold. Free apMNKQ2 (without transfection agents) entered PDAC cells efficiently, retaining anti‑CSC activity. Systemic delivery of free apMNKQ2 accumulated in tumors, was well tolerated up to 400 mg/kg and showed no toxicity. Importantly, 10 mg/kg of apMNKQ2 produced strong antitumor effects in PDX models. Increasing the dose 20‑fold enhanced tumor uptake but not efficacy, suggesting a therapeutic plateau at 10 mg/kg. Conclusions MNK1 plays a central role in PDAC progression and CSC maintenance. apMNKQ2 is a potent anti‑ MNK1 DNA aptamer with robust preclinical activity, including CSC‑targeting and anti‑invasive effects. Its low toxicity,  \n†Alberto Pérez‑Ruiz, Laura Ruiz‑Cañas and Sandra Batres contributed equally to this work.  \n*Correspondence: Sonia Alcalá [salcala@ext.iib. uam.es](salcala@ext.iib. uam.es)[ ](salcala@ext.iib. uam.es)María Elena Martín[m.elena. martin@hrc.es](m.elena. martin@hrc.es)[ ](m.elena. martin@hrc.es)Bruno Sainz Jr.  \n[bsainz@iib. uam.es](bsainz@iib. uam.es)  \nFull list of author information is available at the end of the article  \n© The Author(s) 2026. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder.","cbCaidI4krePxoc0","https://ap.wps.com/l/cbCaidI4krePxoc0","pdf",14040277,26,"English","# Abstract\n## Background\n## Methods\n## Results\n## Conclusions\n# Keywords\n## Background","[{\"question\":\"What disease and biological target does the study focus on?\",\"answer\":\"The study focuses on pancreatic ductal adenocarcinoma (PDAC) and targets MAP kinase-interacting kinase 1 (MNK1), which is implicated in tumor progression and cancer stem cell maintenance.\"},{\"question\":\"How was apMNKQ2 evaluated in the experiments?\",\"answer\":\"apMNKQ2 effects were assessed using PDAC patient-derived xenograft (PDX) cell lines and in vivo mouse models, including assays for viability, apoptosis, cell cycle, migration, EMT, and CSC properties, plus biodistribution and pharmacokinetics.\"},{\"question\":\"What key anti-tumor and anti-CSC outcomes were reported?\",\"answer\":\"apMNKQ2 downregulated MNK1 and anti-apoptotic proteins, disrupted proliferation and cell cycle progression, inhibited migration/angiogenesis and lung colonization, and strongly targeted PDAC CSCs—reducing CSC markers, clonogenicity, and in vivo tumor initiation over 600-fold.\"}]","Aptamer-based inhibition of MNK1 reduces pancreatic ductal adenocarcinoma growth by targeting cancer stem cells | PDF",1790153388,66,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/68e7233b06062ad52398607df39100f3.webp",983,1305,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/95097020b6b698129c50250e228fae34.webp",982,1304,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/da6e074c422bc9549df832b19ef95d61.webp",981,1303,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6b767f05daae5cf4a1faf9902e52da45.webp",980,1301]